Artiva Halts Lead Immune Therapy and Cuts Staff Following Patient Deaths

2026-10-28 companies

San Diego, Wednesday, 28 October 2026.
Artiva Biotherapeutics is eliminating 94% of its workforce and shuttering its lead program after two trial deaths, heavily impacting market confidence in cell therapies for autoimmune diseases.

Artiva’s Decision to Discontinue AlloNK Program

On 27 October 2026, Artiva Biotherapeutics (NASDAQ: ARTV) announced it would discontinue development of its lead cell therapy candidate, AlloNK (AB-101), an off-the-shelf natural killer (NK) cell therapy for autoimmune diseases, after two fatal adverse events occurred in a Phase 2 clinical trial [1][2][3][4][5]. The San Diego-based biotech firm cited insufficient long-term durability of clinical responses as a primary factor in its decision to halt the program, despite earlier observations of B-cell depletion and clinical activity [4][5]. The FDA had previously requested a pause in enrollment and dosing for the Phase 2a study following the first death, which investigators linked to fludarabine-associated neurotoxicity from the conditioning regimen [2][3][5]. The second participant died suddenly approximately two months post-treatment, with the cause classified as undetermined and assessed as unrelated to the therapy or study components [1][2][3][5].

Workforce Reduction and Strategic Review

In tandem with the program’s discontinuation, Artiva revealed plans to eliminate approximately 94% of its workforce, affecting roughly 98 employees, as part of a broader strategic review [2][3][4][5]. The company retained Leerink Partners to explore alternatives, including potential mergers, asset sales, or licensing agreements [2][3][5]. As of 30 September 2026, Artiva held approximately $319.1 million in cash, cash equivalents, and investments, which the company intends to preserve amid the restructuring [2][3][5]. Shares of Artiva slumped 95.313% on the day of the announcement, reflecting investor concerns over the safety and viability of the therapy [6]. The company also canceled an investor webcast originally scheduled for 9 November 2026 and halted presentations at an October 2026 medical meeting [2][3][4][5].

Broader Implications for the Cell Therapy Sector

Artiva’s shutdown marks the third high-profile discontinuation of an autoimmune cell therapy program in 2026, following safety-related pauses at Novartis and Bristol Myers Squibb (BMS) [2][3]. Novartis reported three deaths in August 2026 related to its rap-cel therapy, while BMS disclosed a patient death 44 days after receiving zola-cel in October 2026 [2][3]. These events have cast a shadow over the broader cell therapy sector, particularly for non-oncology indications, where regulatory scrutiny and safety concerns are intensifying [1][2][3][4]. Analyst Tyler Van Buren of TD Cowen noted that despite Artiva’s substantial cash reserves, meaningful share value appreciation was unlikely under current conditions [2]. The company’s decision to explore strategic alternatives, including dissolution or liquidation, underscores the growing challenges faced by biotechs operating in high-risk therapeutic areas [3][5].

Market Reactions and Industry Context

The news triggered a sharp decline in Artiva’s stock price, with shares falling 95.313% following the announcement, and indirectly impacted its South Korean partner, GC Cell, whose stock plunged 17% on 28 October 2026 [6][7]. Artiva’s struggles mirror a broader trend in the biotech industry, which has seen a wave of closures in 2026 despite an otherwise improving market environment [8]. According to Fierce Biotech’s annual “Biotech Graveyard” report, 10 biotech companies had shut down by October 2026, with Artiva joining Adecto Pharmaceuticals, Nido Biosciences, and Arpeggio Biosciences among those forced to wind down operations due to clinical failures or funding constraints [8]. As the sector grapples with heightened regulatory oversight and investor caution, the fallout from Artiva’s decision serves as a cautionary tale for companies pursuing innovative but high-risk therapies [1][2][3][4][8].

Sources

Biotechnology Clinical trials